Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 for hereditary fructose intolerance
NL-OMON53368Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PF-06835919 in Fructosemia (HFI) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Intrahepatic lipid content, Intestinal fructose tolerance and 2 more. Started Jun 2023; status: recruiting.
02
Drugs
PF-06835919
03
Conditions
Fructosemia (HFI)
Beyond the preview
Go deeper on NL-OMON53368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53368.